Assessment of atorvastatin effectiveness on serum PSA level in hypercholesterolemic males

Acta Medica Iranica

Volumn 49, Issue 12, 2011, Pages 789-794

  Khosropanah, Iradj ^a   Falahatkar, Siavash ^a   Farhat, Babak ^a   Bateni, Zhoobin Heidari ^b   Enshaei, Ahmad ^a   Allahkhah, Ali Akbar ^a   Khosropanah, Darya ^a  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atorvastatin; Hypercholesterolemic male; Prostate cancer; Serum PSA level

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LONG TERM CARE; LOW FAT DIET; MALE; PROSPECTIVE STUDY; PROSTATE CANCER; SHORT COURSE THERAPY;

AGED; CHOLESTEROL, LDL; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PYRROLES; TRIGLYCERIDES;

EID: 84856508764     PISSN: 00446025     EISSN: 17359694     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Klein EA, Platz E., Thompson I. Epidemiology, etiology and prevention of prostate cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell- Walsh Urology. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2007. p. 2854-63.
2. Eastham JA, Scardino PT. Expectant management of prostate cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2007. p. 2947.
3. Gretzer MB, Partin AW. Prostate cancer tumor markers. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2007. p. 2896-907.
4. Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther 2001;15(3):211-8.
5. Stark WW Jr, Blaskovich MA, Johnson BA, Qian Y, Vasudevan A, Pitt B, Hamilton AD, Sebti SM, Davies P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol 1998;275(1 Pt 1):L55-63.
6. Buemi M, Allegra A, Senatore M, Marino D, Medici MA, Aloisi C, Di Pasquale G, Corica F. Pro-apoptotic effect of fluvastatin on human smooth muscle cells. Eur J Pharmacol 1999;370(2):201-3.
7. Ukomadu C, Dutta A. Inhibition of cdk2 activating phosphorylation by mevastatin. J Biol Chem 2003;278(7):4840-6.
8. Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003;24(3):453-9.
9. Park C, Lee I, Kang WK. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 2001;22(10):1727-31.
10. Ukomadu C, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem 2003;278(44):43586-94.
11. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005;173(6):1923-5.
12. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98(24):1819-25.
13. Murtola TJ, Tammela TL, Määttänen L, Huhtala H, Platz EA, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer 2010;127(7):1650-9.
14. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004;22(12):2388-94.
15. Newton CJ, Ran G, Xie YX, Bilko D, Burgoyne CH, Adams I, Abidia A, McCollum PT, Atkin SL. Statininduced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 2002;174(1):7-16.
16. Edwards PA, Ericsson J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 1999;68:157-85.
17. Sinensky M. Recent advances in the study of prenylated proteins. Biochim Biophys Acta 2000;1484(2-3):93-106.
18. Pérez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994;199(3):1209-15.
19. Denoyelle C, Vasse M, Körner M, Mishal Z, Ganné F, Vannier JP, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22(8):1139-48.
20. Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol 1980;14(1):29-35.
21. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269(23): 3015-23